- Home
- IH vs ANL Comparison
IH vs ANL Comparison
Compare IH & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IH
- ANL
- Stock Information
- Founded
- IH 1996
- ANL 2004
- Country
- IH China
- ANL Cayman Islands
- Employees
- IH N/A
- ANL N/A
- Industry
- IH Other Consumer Services
- ANL
- Sector
- IH Real Estate
- ANL
- Exchange
- IH Nasdaq
- ANL Nasdaq
- Market Cap
- IH 85.3M
- ANL 84.5M
- IPO Year
- IH 2020
- ANL 2023
- Fundamental
- Price
- IH $1.77
- ANL $2.22
- Analyst Decision
- IH
- ANL Strong Buy
- Analyst Count
- IH 0
- ANL 2
- Target Price
- IH N/A
- ANL $9.00
- AVG Volume (30 Days)
- IH 18.7K
- ANL 9.6K
- Earning Date
- IH 12-26-2024
- ANL 08-08-2024
- Dividend Yield
- IH N/A
- ANL N/A
- EPS Growth
- IH N/A
- ANL N/A
- EPS
- IH 0.33
- ANL N/A
- Revenue
- IH $132,388,363.00
- ANL $5,000,000.00
- Revenue This Year
- IH $15.90
- ANL N/A
- Revenue Next Year
- IH $8.64
- ANL N/A
- P/E Ratio
- IH $5.48
- ANL N/A
- Revenue Growth
- IH N/A
- ANL N/A
- 52 Week Low
- IH $1.47
- ANL $1.85
- 52 Week High
- IH $3.18
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- IH 56.58
- ANL 43.45
- Support Level
- IH $1.68
- ANL $2.23
- Resistance Level
- IH $1.81
- ANL $2.44
- Average True Range (ATR)
- IH 0.08
- ANL 0.19
- MACD
- IH 0.02
- ANL -0.01
- Stochastic Oscillator
- IH 84.62
- ANL 23.43
About IH iHuman Inc.
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources. The majority of iHuman Inc's revenue comes from mainland China.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.